Tape Strips Identified as Non-Invasive Approach to Assess Skin Biomarkers in Children With Atopic Dermatitis
May also help predict therapeutic responses
Applying strips of adhesive tape to skin lesions and non-lesional skin is a non-invasive way to obtain biomarkers to track the severity of early-onset pediatric eczema or atopic dermatitis (AD) in infants and young children, researchers report for the first time. The study, titled “Use of Tape Strips to Detect Immune and Barrier Abnormalities In Early Onset Pediatric Atopic Dermatitis” and led by researchers at the Icahn School of Medicine at Mount Sinai and Northwestern University’s Feinberg School of Medicine, was published online today in Jama Dermatology.
According to the lead author of the paper, Emma Guttman-Yassky, MD, PhD, Sol and Clara Kest Professor and Vice Chair of Dermatology, and Professor of Immunology, at the Icahn School of Medicine, this is the first study to provide a broad characterization of immune and barrier abnormalities in the skin of children with early-onset eczema, those aged five and under who have had eczema for less than six months.
“Up until now, skin tissue biopsies have been considered the gold standard for evaluating dysregulation in lesional and non-lesional AD/eczema skin,” said Dr. Guttman-Yassky. “Therefore, it has been crucial to understand whether profiling of the tiny amounts of RNA obtained from the outer layers of the skin using tape strips can accurately yield key biomarkers for AD.”
Dr. Guttman-Yassky and her team of researchers at the Icahn School of Medicine at Mount Sinai discovered that tape strips applied several times to the same skin areas provide a perfect classifier to discriminate between early-onset AD skin and normal pediatric skin, including biomarkers pathogenically linked to AD. “This work can be highly informative for longitudinal studies in infants and children and in clinical trials for both children and adults,” said Dr. Guttman-Yassky, whose past revolutionary research on AD/eczema focused on the mechanism underlying the disease and promoted development of targeted therapeutics for eczema, and who has identified biomarkers to track improvement with current treatments for the disease.
Atopic dermatitis is an inflammatory, extremely itchy skin disorder that affects 10 to 20 percent of children in the United States and more than 31 million adults.
Amy S. Paller, MD, Walter J. Hamlin Professor and Chair of Dermatology at Northwestern and a senior author, said, “While skin biopsies are simple to perform in adults as a way to obtain skin to assess for biomarkers that allow prediction of course and responses to targeted medications, they are nearly impossible to obtain in children, especially small children. We have now demonstrated that tape strips can be used to obtain skin for quantifying expression of numerous genes that are important markers of both immune and barrier function in AD in young children.”
The researchers investigated a total of 51 children younger than five, some with moderate to severe eczema and others without eczema, from an outpatient dermatology clinic at a children’s hospital. Sixteen tape strips were collected from each of the skin of 21 lesional and non-lesional children who had AD and were less than six months from disease initiation, and from the skin of 30 normal children who did not have AD, between January 2016 and April 2018. Gene and protein expression were then evaluated using real-time polymerase chain reaction and immunohistochemistory.
Said Dr. Guttman-Yassky, “Being able to noninvasively collect skin in children for this study paves the way for future studies to better understand a wide variety of skin disorders as well as to start identifying markers to predict course, comorbidities, and treatment response in prospective studies.”
Additionally, the same tape strips can be used for collection and analysis of the skin microbiome (bacterial and viral inhabitants of the skin’s surface), allowing investigations that compare changes in the skin microbial population and gene/protein changes.
Mark Lebwohl, MD, Waldman Professor of Dermatology and Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, said, “This important study emphasizes the great need of better understanding immune and barrier alterations in pediatric skin. Dr. Guttman-Yassky’s revolutionary research is continuing to open the door to new therapeutic discoveries by helping to improve the quality of lives of both adults and children with eczema and beyond.
The study was supported by grant NIAMS P30 ARO57216 from the Northwestern University Skin Disease Research Center and grant UL1TR001422 from the Northwestern Clinical Translational Sciences Institute. Research was supported in part by a grant from Regeneron and Sanofi.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Mount Sinai Researchers Discover That Topical Treatment Improves Chronic Plaque Psoriasis
Jul 15, 2020 View All Press Releases